Altamira Therapeutics Ltd. (CYTO)
After hours:
| Previous close | 1.5500 |
| Open | 1.5800 |
| Bid | 1.1000 x 200 |
| Ask | 1.9200 x 200 |
| Day's range | 1.4501 - 1.5850 |
| 52-week range | 1.3500 - 23.6000 |
| Volume | |
| Avg. volume | 1,194,714 |
| Market cap | 3.495M |
| Beta (5Y monthly) | 2.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -16.3200 |
| Earnings date | 10 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAltamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has filed a provisional patent application with the United States Patent O
- GlobeNewswire
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy endpoint of improvement in nasal symptoms (p = 0.013) Corroborated by statistically significant improvement in health-related quality of life and reduced need for relief medicationStudy outcomes support plans for further international expansion HAMILTON, BERMUDA -- April 24, 2024 -- Altamira Therapeu
- GlobeNewswire
Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 18, 2024
Presenting Companies to Host 25-Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Spotlight Investor Conference on April 18, 2024. The conference, which is open to all retail and institutional investors, will consist of a series of twenty-five-minute presentations by public
